Clinical Trials
96 trialsNCT05523440 2026-06-03
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT05039801 2026-06-01
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05231122 2026-06-01
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06083844 2026-05-18
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06023862 2026-05-06
DOVE
Yonsei University
Phase 2 Recruiting
NCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT07340164 2026-04-20
TROY
Yonsei University
Phase 2 Recruiting
NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06580314 2026-03-24
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT04919629 2026-03-23
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT02884648 2026-02-06
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05636111 2026-01-22
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06971744 2025-12-22
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Phase 2 Recruiting
NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT07117877 2025-08-28
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06540729 2025-07-08
DAB
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06954584 2025-06-24
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Tongji Hospital
Phase 3 Recruiting
NCT06292286 2025-06-11
SCENIC
The University of Hong Kong
Phase NA Recruiting
NCT05044871 2025-06-08
BRIGHT
Tongji Hospital
Phase 2 Completed
NCT06990516 2025-05-25
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT01220154 2025-02-21
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT06827353 2025-02-14
OVNI-B
Centre Hospitalier Universitaire de NÄ«mes
Recruiting
NCT02891824 2025-02-11
ATALANTE
ARCAGY/ GINECO GROUP
Phase 3 Completed
NCT06735326 2024-12-16
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT06650709 2024-10-23
NEOCATS
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT03596281 2024-10-18
PEMBOV
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT04787289 2024-08-07
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
British Columbia Cancer Agency
Phase 2 Recruiting
NCT06377267 2024-05-09
STROBE
Vall d'Hebron Institute of Oncology
Phase 2 Unknown
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06307249 2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1 Recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT06063070 2023-10-02
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT03363867 2023-08-07
BEACON
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05819060 2023-04-19
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Fudan University
Phase 2 Unknown
NCT01706120 2023-03-24
MITO16/MANGO-2
National Cancer Institute, Naples
Phase 4 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT04753216 2023-01-19
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Northwestern University
Phase 2 Completed
NCT01097746 2022-10-28
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05551208 2022-09-22
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT02354131 2022-08-30
AVANOVA
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 1/2 Completed
NCT01462890 2022-07-20
BOOST
AGO Study Group
Phase 3 Completed
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT05310344 2022-04-04
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown